Skip to main content
AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

FDA flags rare eye risk for GLP-1 drugs

NEWS

November 9, 2026 at 16:41 UTC

3 min read
Unbranded GLP-1 injection pen on exam table with blurred eye chart, reflecting FDA warning on rare eye risk

Key Points

  • 01FDA cites potential increased risk of rare eye condition NAION with GLP-1 drugs
  • 02All GLP-1 receptor agonists must add new warnings and precautions to labels
  • 03Meta-analysis found NAION incidence of 6.4 vs 3.8 cases per 100,000 person-years
  • 04Patients and doctors are urged to watch for sudden vision changes in one eye

FDA adds eye risk warning to GLP-1 drug labels

The U.S. Food and Drug Administration has ordered safety labeling changes for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications, citing a potential increased risk of a rare but serious eye condition. On November 9, 2026, the agency said application holders must add information to the Warnings and Precautions section of product labels about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients using these drugs.

The requirement applies to GLP-1 drugs used for both diabetes and weight loss, including Eli Lilly (LLY)’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy. The move follows an FDA drug safety communication informing patients and health care providers that NAION has been reported across all currently marketed GLP-1 RA products.

Nature and severity of the NAION risk

NAION is described as a rare condition that can cause acute, painless, decreased vision in one eye and can lead to permanent vision loss. It is sometimes referred to as an eye stroke and is caused by insufficient blood flow to the optic nerve. The FDA notes that sudden vision loss is typical and that there are currently no proven treatments for the condition.

Reported symptoms include sudden, painless vision loss in one eye, blurred or missing portions of vision such as blind spots or tunnel vision, distortion of colors and reduced central sharpness, including blurry or hazy spots. The agency emphasizes that patients and caregivers should be aware of these potential signs when using GLP-1 RAs.

Evidence behind the safety action

To assess the potential association between GLP-1 RA use and NAION, the FDA evaluated clinical trial data, animal data and postmarketing information, including observational studies and case reports. A meta-analysis of 126 randomized, controlled clinical trials covering 134,253 patients and 288,879 person-years of exposure was conducted across GLP-1 RA development programs.

In this analysis, the incidence of NAION was 6.4 events per 100,000 person-years in patients treated with GLP-1 RAs, compared with 3.8 events per 100,000 person-years in patients receiving placebos or non-GLP-1 RA glucose-lowering medications. The FDA also reviewed observational studies in patients with type 2 diabetes that consistently found an increased risk of NAION among those who initiated GLP-1 RAs compared with those who started DPP-4 inhibitors or SGLT-2 inhibitors.

Further analyses showed no statistically significant increase in NAION risk when GLP-1 RAs were compared with SGLT-2 inhibitors, but an increased risk was observed versus DPP-4 inhibitors, with a hazard ratio of 1.43 and a 95% confidence interval of 1.02 to 2.01. Animal data reviewed by the FDA did not identify a mechanism explaining how GLP-1 RA use could increase NAION risk.

Guidance for patients and health professionals

The FDA advises patients and caregivers using GLP-1 RAs to be alert to sudden onset of vision changes, including painless decreased vision, visual field defects or other visual disturbances in one eye, and to seek prompt medical attention. Health care professionals are urged to instruct patients to report such symptoms immediately and to refer suspected cases of NAION to an ophthalmologist for evaluation.

Clinicians are also advised to consider discontinuing GLP-1 RA therapy in patients who develop NAION, unless the benefits of continued treatment clearly outweigh the risk. While GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have grown rapidly in use for their blood glucose and weight loss effects, regulators now require that information on this rare but serious eye risk be clearly communicated in product labeling.

Key Takeaways

  • 01Regulators now formally recognize a potential increased risk of NAION across the GLP-1 RA class, prompting a broad update to drug safety labels.
  • 02Although NAION remains rare, the combination of clinical trial and observational data was sufficient to trigger new warning and monitoring requirements.
  • 03Ongoing GLP-1 RA treatment decisions will need to balance established metabolic benefits against the newly highlighted potential for serious, irreversible eye damage.

FDA flags rare eye risk for GLP-1 drugs | Trading Dashboard